Positive preliminary results for “Pfizer” pills against “Covid 19”


Positive preliminary results for “Pfizer” pills against “Covid 19”

Clinical tests confirmed its efficacy with 89%, a day after Britain approved Merck.

Saturday – 1 Rabi’ al-Thani 1443 AH – 06 November 2021 AD Issue No. [

Biden, when giving a speech at the White House yesterday (AP), “Pfizer” confirmed the effectiveness of its drug (AFP).

Washington: Asharq Al-Awsat.

The “Pfizer” company announced yesterday (Friday), that the clinical tests conducted for the first pill of its kind that it produced to treat patients with “Covid-19” show that it is highly effective. The drug is the second of its kind after the pills produced by the company “Merck”, and approved by Britain the day before yesterday.
Yesterday, US President Joe Biden said that the United States has millions of doses of the experimental antiviral tablets “Pfizer” to treat “Covid-19”, if it turns out to be an effective treatment. “If the US Food and Drug Administration clears it, we may soon get pills that treat the virus for those who have contracted it,” Biden said. “We already have millions of doses,” he added. This treatment will be another tool in our toolbox to protect people from the worst consequences of (Covid-19).”
The drug, called “Paxlovid”, succeeded by 89 percent in reducing the risk of transferring patients to hospitals or the death of many adults with “Covid-19” who are most at risk of severe disease, according to clinical results.
The company that markets one of the main vaccines against “Covid-19”, said that it intends to submit these results “as soon as possible” to the Food and Drug Administration, to obtain permission to use the drug in an emergency, as reported by the French press agency.
The UK was the first country to market a similar treatment developed by the US Merck group, while it is being studied in the US and Europe. Antiviral drugs work by reducing the ability of the virus to reproduce, and thus slowing the disease, and these treatments represent a complement to vaccines to protect against “Covid-19.”
Pfizer’s preliminary results are based on clinical trials conducted on more than 1,200 adults who had “Covid-19” and were at risk of developing a severe case of the disease.
Days after the onset of symptoms, some were given Pfizer tablets and others were given a placebo for five days, once every 12 hours.
“Preliminary analysis showed an 89 percent reduction in acute illness and death, compared to placebo, in patients treated three days after symptom onset,” Pfizer said in a statement. Similar results were observed in patients treated five days after the onset of symptoms.
In all, 10 people died among the patients who received the placebo, compared with zero deaths among the group that received the treatment.
And “Pfizer” indicated that the experiment was supposed to include three thousand people, but the group will stop looking for new people to undergo tests “given the overwhelming effectiveness” of the treatment in the first results. “Today’s news represents a real game-changer in the global effort to stem the devastation caused by this pandemic,” said Albert Burla, CEO of Pfizer. He added, “These data indicate that our oral anti-viral drug, if approved or licensed by regulatory bodies, will be able to save patients’ lives, reduce the severity of (Covid) infections, and prevent the need to transfer nine out of ten cases to hospitals.”
Pfizer’s treatment will be marketed under the name “Baxiloid”. The laboratory is currently conducting two other clinical trials; The first is to assess the effectiveness of the pills in people who are not at increased risk of severe disease.
As for the second experiment, it will be about the ability of treatment to reduce the preventive risk of transmission of infection between those around a person with the disease.
In addition to Merck and Pfizer, Roche is also developing similar pills. Pfizer began developing the drug in March 2020.


new corona virus


Please enter your comment!
Please enter your name here